Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:43 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 315 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Interferon Alpha Clear all

Conditions: Leukemia
Interventions: GM-K562 cell vaccine, Interferon alfa, Sargramostim; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Melanoma
Interventions: administration of ipilimumab10mg/kg, administration of ipilimumab 3mg/kg + HDI; Drug
Lead sponsor: Diwakar Davar; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Clear Cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions: sorafenib tosylate, recombinant interferon alfa, laboratory biomarker analysis; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Memory Disorders, Alzheimer's Disease
Interventions: Aricept, IFN-alpha2A; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 50 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV Infections
Interventions: Interferon alfa-n3; Drug
Lead sponsor: Interferon Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New York, New York

Conditions: Pancreatic Cancer
Interventions: Pancreatic Surgery, Radiation therapy, Cisplatin, 5-FU, Alpha-interferon, Gemcitabine; Procedure · Radiation · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: aldesleukin, recombinant interferon alfa; Biological
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 1999
U.S. locations: 5
States / cities: Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 2 more

Conditions: Basal Cell Carcinoma
Interventions: Imiquimod and Interferon alpha; Biological
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: Not listed
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia
Interventions: recombinant interferon alfa, imatinib mesylate; Biological · Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 2
States / cities: Chicago, Illinois • Portland, Oregon

Conditions: Melanoma
Interventions: Temozolomide, Abraxane, Cisplatin, Interleukin-2, Interferon alpha 2b; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Leukemia
Interventions: cyclophosphamide, filgrastim, recombinant interferon alfa, peripheral blood stem cell transplantation, radiation therapy; Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Stem Cell Transplantation
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 2 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Systemic Lupus Erythematosus, SLE, Lupus
Interventions: Vitamin D3, Vitamin D3 placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 8
States / cities: Birmingham, Alabama • San Francisco, California • Boston, Massachusetts + 5 more

Conditions: Cervical Cancer, Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Non-melanomatous Skin Cancer, Penile Cancer
Interventions: recombinant interferon alfa, isotretinoin; Biological · Drug
Lead sponsor: Hoag Memorial Hospital Presbyterian; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1992 – 1999
U.S. locations: 6
States / cities: Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 3 more

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: recombinant interferon-α, recombinant interleukin-6; Biological
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 120 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Extrahepatic Bile Duct Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer, Pancreatic Cancer, Small Intestine Cancer
Interventions: filgrastim, recombinant interferon alfa, fluorouracil, hydroxyurea; Biological · Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2000
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: HIV Infections
Interventions: CD4-IgG, Zidovudine, Interferon alfa-n1, Peripheral lymphocyte infusion, Bone marrow transplant; Drug · Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Chronic Hepatitis C
Interventions: albumin interferon alfa-2b, peginterferon alfa-2a, Ribavirin; Drug
Lead sponsor: Human Genome Sciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 933 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 28
States / cities: Phoenix, Arizona • La Jolla, California • San Francisco, California + 20 more

Conditions: HIV Infection
Interventions: Pegylated Interferon Alpha 2b (PEGINTRON); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 2
States / cities: Bethesda, Maryland • Pittsburgh, Pennsylvania

Conditions: HIV Infections, Hepatitis C
Interventions: Interferon alfa-2b, Zidovudine, Zalcitabine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1996
U.S. locations: 3
States / cities: Los Angeles, California • Indianapolis, Indiana • New York, New York

Conditions: Hepatitis C
Interventions: Interferon alpha; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Lupus Erythematosus, Systemic, Lupus
Interventions: MEDI-545, Placebo; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 22
States / cities: Anniston, Alabama • Huntington Beach, California • Upland, California + 19 more

Conditions: Leukemia
Interventions: busulfan, cyclophosphamide, filgrastim, recombinant interferon alfa, in vitro-treated peripheral blood stem cell transplantation, peripheral blood stem cell transplantation, radiation therapy; Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Lymphoma
Interventions: Pegylated interferon α-2b, Psoralens with ultraviolet light A, Narrowband-ultraviolet light B; Biological · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 120 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI

Neoadjuvant Combination Therapy With Ipilimumab and HighDose IFN-α2b for Melanoma

Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha

Double-Blind, Randomized, Dose Ranging Study of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) in HIV+ Subjects

Chemotherapy and Radiation Following Pancreatic Surgery

Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer

Intron-A/Aldara Combination Therapy for Basal Cell Carcinoma (BCC)

Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia

Cisplatin, Temozolomide, Abraxane, With Interleukin-2 and Interferon for Metastatic Melanoma

Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous Leukemia

Investigating Cytokine Genes of Stem Cell Donors

Vitamin D3 in Systemic Lupus Erythematosus

Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer

Interferon Alfa and Interleukin-6 in Treating Patients With Recurrent Multiple Myeloma

Combination Chemotherapy Plus Interferon Alfa Followed by Filgrastim in Treating Patients With Gastrointestinal Tract Cancer

An Open Trial Combining Zidovudine, Interferon-alfa, and Recombinant CD4-IgG With Transplantation of Syngeneic Bone Marrow and Peripheral Blood Lymphocytes From Healthy gp160-Immunized Donors in the Treatment of Patients With HIV Infection

Efficacy of Albumin Interferon Alfa-2b With Ribavirin Compared to Peg-IFN Alfa-2a With Ribavirin in IFN Naive Patients Geno2/3

Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy

The Safety and Effectiveness of a Two-Drug Combination in the Treatment of Patients With Hepatitis C Plus Advanced HIV Infections

Interferon-Induced Gene Expression in Liver Cells and Peripheral Blood Lymphocytes

A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus

Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous Leukemia

Study of Pegylated Interferon-Alfa 2b in Combination With PUVA Therapy In CTCL